ibi-322
mAbexperimentalBi-specific
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 30, 2020 (NCT04328831)
Timeline
Indications
Mechanism of action
- Programmed cell death 1 ligand 1ANTAGONIST
PDL1
- Leukocyte surface antigen CD47ANTAGONIST
CD47
- Leukocyte surface antigen CD47INHIBITOR
CD47 inhibitor
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05296603 | Phase 2 | Jul 20, 2022 | Central South University |
| NCT05296278 | Phase 2 | Jul 20, 2022 | Central South University |
| NCT05148442 | Phase 1 | Dec 31, 2021 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT04912466 | Phase 1 | Jun 20, 2021 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT04795128 | Phase 1 | May 7, 2021 | Innovent Biologics (Suzhou) Co. Ltd., Zhejiang University |
| NCT04338659 | Phase 1 | Apr 30, 2021 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT04328831 | Phase 1 | Apr 30, 2020 | Innovent Biologics (Suzhou) Co. Ltd. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Innovent Biologics (Suzhou) Co. Ltd. | For profit | 5 | 5 | 1 | 2020 |
| Central South University | Academic/Hospital | 2 | 2 | 1 | 2022 |
| Zhejiang University | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1